HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications
Status:
Active, not recruiting
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
Pancreatic resections carry a high risk for complications, especially pancreatic fistula.
Both hydrocortisone and pasireotide have been shown to be effective in reducing complications
in earlier RCTs. The aim of this study is to compare the effectiveness and safety of these
two drugs in preventing complications of pancreatic surgery.